Abstract
Objective: To determine if a direct measure of instrumental activities of daily living (IADL) scale designed for use with dementia patients can detect differences between persons with mild cognitive impairment (MCI) and normal elderly control subjects (NC). Methods: This study used cross-sectional and longitudinal IADL scale data from MCI and NC subjects followed at an Alzheimers Disease Center. Results: On a 52-point scale, MCI subjects (n = 30) scored significantly lower than NC subjects (n = 30) on the IADL scale (total score 47.17 vs. 48.77 points; t (58) = 2.34, p = .011) and its Memory subscale (5.27 vs. 6.6 points; t (58) = 3.29, p = .002).Examination of annualized IADL scale change scores revealed that 50% of MCI subjects had declined by one point, compared with 29% of NC. Conclusion: A direct IADL measure for dementia patients is able to detect small differences between MCI and NC and cross-sectionally and longitudinally, but does not distinguish between groups.
Keywords: Mild cognitive impairment, IADL, Texas Functional Living Scale
Current Alzheimer Research
Title: Can a Direct IADL Measure Detect Deficits in Persons with MCI?
Volume: 6 Issue: 1
Author(s): Dani L. Binegar, Linda S. Hynan, Laura H. Lacritz, Myron F. Weiner and C. Munro Cullum
Affiliation:
Keywords: Mild cognitive impairment, IADL, Texas Functional Living Scale
Abstract: Objective: To determine if a direct measure of instrumental activities of daily living (IADL) scale designed for use with dementia patients can detect differences between persons with mild cognitive impairment (MCI) and normal elderly control subjects (NC). Methods: This study used cross-sectional and longitudinal IADL scale data from MCI and NC subjects followed at an Alzheimers Disease Center. Results: On a 52-point scale, MCI subjects (n = 30) scored significantly lower than NC subjects (n = 30) on the IADL scale (total score 47.17 vs. 48.77 points; t (58) = 2.34, p = .011) and its Memory subscale (5.27 vs. 6.6 points; t (58) = 3.29, p = .002).Examination of annualized IADL scale change scores revealed that 50% of MCI subjects had declined by one point, compared with 29% of NC. Conclusion: A direct IADL measure for dementia patients is able to detect small differences between MCI and NC and cross-sectionally and longitudinally, but does not distinguish between groups.
Export Options
About this article
Cite this article as:
Binegar L. Dani, Hynan S. Linda, Lacritz H. Laura, Weiner F. Myron and Cullum Munro C., Can a Direct IADL Measure Detect Deficits in Persons with MCI?, Current Alzheimer Research 2009; 6 (1) . https://dx.doi.org/10.2174/156720509787313880
DOI https://dx.doi.org/10.2174/156720509787313880 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: Pain in Dementia: A Distressing Combination of Several Factors
Current Alzheimer Research Multifunctional Tacrine Derivatives in Alzheimer’s Disease
Current Topics in Medicinal Chemistry Vitamin D and Cardiovascular Disease: A Novel Agent for Reducing Cardiovascular Risk?
Current Vascular Pharmacology Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) The Role of Vascular Factors in Late-Onset Sporadic Alzheimers Disease. Genetic and Molecular Aspects
Current Alzheimer Research Predicted Fold for the Abri Amyloid Subunit: A Model for Amyloidogenesis in Familial British Dementia
Protein & Peptide Letters Detection of Cognitive Impairment by Choice Auditory Reaction Time (ART) and Visual Reaction Time (VRT)s during Acute Mental Stress in Young Hypertensives: A Case Control Study
Current Hypertension Reviews Efficacy of Pentoxifylline in the Management of Microalbuminuria in Patients with Diabetes
Current Diabetes Reviews Protein Aggregation in Neurodegenerative Diseases: Insights from Computational Analyses
Current Bioinformatics Inhalation Gases or Gaseous Mediators As Neuroprotectants for Cerebral Ischaemia
Current Drug Targets Sculpted Amphiphilic Liposomal Particles for Modifiable Medicinal Applications
Current Drug Discovery Technologies Thrombolytic Therapy in Acute Ischemic Stroke - Basic Concepts
Current Vascular Pharmacology Lipid Biomarkers in Alzheimer's Disease
Current Alzheimer Research Targeting CNS Transporters for Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Evaluation of Mental Status HIV-Infected Patients: Implications for Treatment
Current HIV Research The Roles of Phosphodiesterase 2 in the Central Nervous and Peripheral Systems
Current Pharmaceutical Design Molecular Imaging of Apoptosis In Vivo with Scintigraphic and Optical Biomarkers – A Status Report
Anti-Cancer Agents in Medicinal Chemistry Proniosomes in Transdermal Drug Delivery
Current Pharmaceutical Design Effects of Yokukansan, a Japanese Kampo Medicine for Symptoms Associated Autism Spectrum Disorder
CNS & Neurological Disorders - Drug Targets Antagonism of Endothelin (ETA and ETB) Receptors During Renovascular Hypertension-Induced Vascular Dementia Improves Cognition
Current Neurovascular Research